{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 3 Continuous Glucose Monitoring System",
        "FreeStyle Libre 3 Sensor",
        "FreeStyle Libre 3 App"
    ],
    "Submitter Information": "Abbott Diabetes Care, Inc.",
    "510(k) Number": "K213996",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210943"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLG"
    ],
    "Summary Letter Date": "April 8, 2022",
    "Summary Letter Received Date": "April 11, 2022",
    "Submission Date": "May 16, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine",
        "POCT"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "Sensor (on-body, back of upper arm)"
    ],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 3 Sensor",
        "FreeStyle Libre 3 App (Android)",
        "Compatible Android-enabled smartphones"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Bluetooth Low Energy (BLE) communication",
        "Near Field Communication (NFC)",
        "Electrochemical sensor"
    ],
    "Methodologies": [
        "Continuous glucose monitoring",
        "Electrochemical sensing",
        "Factory calibration"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Mobile application",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for FreeStyle Libre 3 integrated continuous glucose monitoring system using on-body sensor and mobile app for real-time glucose measurement in diabetes management.",
    "Indications for Use Summary": "Real time continuous glucose monitoring system with alarms for diabetes management in persons age 4+; replaces blood glucose testing for therapy decisions, detects glycemic episodes, and communicates with digitally connected devices.",
    "fda_folder": "Clinical Chemistry"
}